Assisted Dying Advocates Deflated
















More than 1.5 million Massachusetts voters said “no” to a ballot measure last week that would have allowed doctor-assisted suicide for the terminally ill, clinching a 51 percent majority. Jim Carberry might have been one of them, had he not watched his cancer-stricken wife starve herself to death.


Margie Carberry had four surgeries and 44 doses of radiation for a rare spinal tumor before doctors said “there was nothing more they could do.”













“By that point, she was just existing,” said Jim Carberry of Natick, Mass., recalling the 16-year cancer battle that left his wife unable to walk, talk, eat and even breathe on her own. “She started seeing the palliative care team at Mass General, as well as a social worker and her minister. And she told them all on numerous occasions that after our youngest daughter’s graduation, she wanted to die.”


Margie made it to the graduation ceremony, a milestone she imagined when at the time of her diagnosis when her daughters were 2 and 5 years old. A week later, she decided to die by removing her feeding tube.


“She exercised the only option she had,” said Carberry of the agonizing process that spanned five weeks in the summer of 2011. “It was horrendous watching her waste away, having my children watch her waste away. I decided that if there was anything I could do to help another family avoid this, I would do it.”


Carberry became a voice for Death With Dignity, a national campaign to let doctors prescribe life-ending medication to terminally ill patients. Assisted dying laws have already been passed in Oregon and Washington. And on Nov. 6, the issue was on the Massachusetts ballot as “Question 2.” The measure was met with fierce opposition by religious, medical and disability rights groups.


“I honestly thought we would win,” said Carberry, who was devastated by the narrow defeat. “The fact that we lost by such a close margin, and the fact that the other side was funded by some outside groups who really didn’t have a dog in this fight, I won’t lie, I’m really angry.”


One of the groups, the Committee Against Assisted Suicide, argued Question 2 was “poorly written, confusing and flawed,” opening the door for depressed patients to take their lives before getting mental health counseling or seeking hospice care.


”We believe the voters came to see this as a flawed approach to end of life care, lacking in the most basic safeguards,” committee chairwoman Rosanne Bacon Meade said in a statement to the Associated Press. ”We hope this marks the beginning of a real conversation about ways to improve end-of-life care in Massachusetts, which, as the nation’s health care capital, is well positioned to take the lead on this issue.”


Assisted dying advocates argue data from Oregon, where the Death With Dignity Act was passed in 1994, refutes concerns about safeguards and plan to push for the ballot measure again in 2014.


“The foundation for support has been built, and we’ll keep working to make sure voters in Massachusetts and other states get the facts they need for an open and honest debate about Death with Dignity,” Peg Sandeen, executive director of the Death With Dignity National Center, said in a statement.


Carberry admits his position on Question 2 was undoubtedly influenced by his personal experience, which he did his best to share in advance of the vote.


“If someone could watch what my family went through all the way to the end and say, ‘That’s how I want my loved one to pass away,’ then there’s nothing I can do,” he said. “But anyone who has an iota of compassion in the heart, I can’t see them saying that.”


Health News Headlines – Yahoo! News



Read More..

S&P 500 and Nasdaq inch higher, fiscal cliff a concern
















NEW YORK (Reuters) – Stocks mostly ticked higher on Monday, but persistent concerns about the upcoming debate on the fiscal cliff limited gains even after last week’s steep sell-off.


Barclays cut its year-end target for the S&P 500 to 1,325, citing fiscal cliff issues.













The S&P 500 dropped 2.4 percent last week, the worst week for the benchmark index since June. It closed below its 200-day moving average for the first time in five months, and an extended run under that level could signal further losses ahead.


Trading volume is expected to be light, with the U.S. bond market and government offices closed on Monday for the Veterans Day holiday.


Last week’s weakness was partly propelled by concerns about whether there will be a timely solution to avoid the fiscal cliff, a combination of government spending cuts and tax increases set to go into effect early next year unless Congress acts to change the law before then. Though most consider it unlikely that no deal will be reached, analysts fear going over the cliff could push the economy back into recession


“Right now, all eyes are on Washington, and we’re just waiting,” said Matthew Keator, a partner in the Keator Group, a wealth management firm in Lenox, Massachusetts. “We’re hopeful something gets done, but we’ve been disappointed before. We need to see something done if we’re going to remain up for the year.”


The S&P 500 is still up 10 percent for 2012, though recent months have eroded those gains. The Nasdaq has fallen for five straight weeks.


The Dow Jones industrial average <.DJI> was down 3.69 points, or 0.03 percent, at 12,811.70. The Standard & Poor’s 500 Index <.SPX> was up 0.87 of a point, or 0.06 percent, at 1,380.72. The Nasdaq Composite Index <.IXIC> was up 4.53 points, or 0.16 percent, at 2,909.41.


Some major acquisition news gave investors some reasons for optimism on Monday. Precision Castparts Corp offered to buy Titanium Metals Corp for $ 2.9 billion, while Leucadia National Corp agreed to buy investment bank Jefferies Group for $ 3.6 billion.


Shares of Titanium surged 42.3 percent to $ 16.46 while Jefferies climbed 13.5 percent to $ 16.19. Precision rose 5.5 percent to $ 180.67. In contrast, Leucadia fell 4 percent to $ 20.93.


“After last week, there could be some bargain opportunities out there,” said Keator, who helps oversee $ 500 million in assets. “Especially since if there is a fiscal cliff deal, that could lead to a tremendous move on the upside.”


Overseas, a report over the weekend showed China’s export growth climbed to a five-month high, beating expectations and adding to recent data suggesting the country’s seven straight quarters of slowing economic growth have ended.


In addition, the Greek parliament on Sunday approved an austerity budget for next year, a necessary step to unblock a new tranche of credit from the European Union and International Monetary Fund before the government runs out of cash. Still, investors remain concerned about whether the EU and IMF will agree to send the next tranche.


Apple Inc rose 0.6 percent to $ 550.42 after the company announced a global patent settlement with HTC Corp <2498.TW>, as well as a 10-year licensing agreement. Apple‘s stock has been under pressure recently, dropping more than 20 percent from its 2012 high to enter bear market territory.


Homebuilder D.R. Horton Inc reported fourth-quarter earnings that beat expectations, helped by a jump in orders. D.R. Horton‘s shares gained 3.1 percent to $ 21.23.


According to Thomson Reuters data through Friday, of the 449 companies in the S&P 500 that have reported earnings, 63.3 percent have topped expectations. But only 38.2 percent of companies have topped revenue expectations – well below the 62 percent average since 2002.


(Editing by Jan Paschal)


Business News Headlines – Yahoo! News



Read More..

Israel kills Gaza rocket crewman in second day of clashes
















GAZA (Reuters) – An Israeli air strike killed a Palestinian militant in the Hamas-governed Gaza Strip on Sunday as a surge in cross-border violence entered its second day, local officials said.


Islamic Jihad, a smaller faction than Hamas which often operates independently, identified the dead man as one of its own, saying he was a member of a rocket crew hit by an Israeli missile in Jabalya, northern Gaza.













The Israeli military confirmed carrying out an air strike in the area. The death brought to six the number of Palestinians killed by Israel since four of its troops were hurt in a missile attack on their jeep along the Gaza boundary fence.


Islamic Jihad said it had fired 70 short-range rockets and mortar bombs across the border since Saturday, salvoes which drove Israeli residents to blast shelters. At least one Israeli, in the town of Sderot, was wounded, ambulance workers said.


Israel described the jeep ambush as part of a Palestinian strategy of trying to curb its countermeasures against possible cross-border infiltration. Israeli forces often mount hunts for tunnels and landmines on the inside of the Gaza boundary, creating a no-go zone for Palestinians.


“Of course we don’t accept their attempt to change the rules,” Defence Minister Ehud Barak told Israel’s Army Radio.


“The essence of the struggle is over the fence. We intend to enable the IDF (Israel Defence Forces) to work not just on our side but on the other side as well.”


Palestinians said four of Saturday’s dead were civilians hit by an Israeli tank shell while paying respects at a crowded mourning tent in Gaza’s Shijaia neighborhood. Israel denies targeting civilians.


The bloodshed puts internal pressure on Hamas, which, though hostile to the Jewish state, has sat out some of the recent rounds of violence as it tried to consolidate its Gaza rule and reach out to neighboring Egypt and other foreign powers.


Israel blames Hamas for any attacks emanating from Gaza, but has shown little appetite for a major sweep of the territory which might strain its own fraught ties to the new Islamist-rooted government in Cairo.


(Writing by Dan Williams; Reporting by Nidal al-Mughrabi; Editing by Todd Eastham)


World News Headlines – Yahoo! News



Read More..

Bond bounds back to top of box office in “Skyfall”
















LOS ANGELES (Reuters) – The new James Bond movieSkyfall” dominated movie box offices with $ 87.8 million in ticket sales in its U.S. and Canadian debut over the weekend for the biggest Bond opening ever, according to studio estimates released on Sunday.


Skyfall,” starring Daniel Craig as the famous super-spy, finished ahead of last weekend’s winner, family film “Wreck-It Ralph.” The animated Walt Disney Co movie about a videogame character grabbed $ 33.1 million from Friday through Sunday.













In third place, the Denzel Washington drama “Flight” earned $ 15.1 million. The movie tells the story of an airline captain who saves his plane from crashing but is accused of drinking before the flight.


Sony Corp’s movie studio released “Skyfall.” “Flight” was distributed by Paramount Pictures, a unit of Viacom Inc.


(Reporting by Lisa Richwine; Editing by Will Dunham)


Movies News Headlines – Yahoo! News



Read More..

Novartis drug helps patients with rare inflammatory diseases
















ZURICH (Reuters) – Novartis‘ Ilaris helps reduce patients’ symptoms and the frequency of attacks in two rare inflammatory diseases, mid-stage studies showed, as the Swiss drugmaker looks to expand the use of the medicine.


Results of two separate studies on Sunday in patients with Familial Mediterranean Fever (FMF) and TRAPS – rare genetic diseases which can cause fever, rash and joint pain – both met their primary endpoints, Novartis said in a statement.













Both studies are being presented at the American College of Rheumatology (ACR) meeting in Washington D.C.


Ilaris or ACZ885, which blocks a protein called interleukin-1 beta that is thought to increase inflammation, is already sold for treating cryopyrin-associated periodic syndromes, a rare inflammatory disorder.


Novartis is also hoping to file the drug this year for regulatory approval in systemic juvenile idiopathic arthritis (SJIA), a debilitating disease that can affect a child’s growth.


Results of the phase II study showed the drug helped 100 percent of FMF patients reduce the frequency of attacks by at least 50 percent during three months of treatment.


Eight of the nine patients in the trial did not have an attack during the three months and blood markers of inflammation also normalized.


There are currently no approved treatments for FMF or TRAPS, rare genetically-inherited anti-inflammatory diseases, which can affect both children and adults.


Novartis is hoping to show the drug can be beneficial in treating rare inflammatory diseases after receiving a setback last year when U.S. health regulators rejected Ilaris for use in gout over concerns about side effects.


New data from a mid-stage study on the use of Ilaris in TRAPS showed that patients who came off therapy after being treated with the drug did not have a relapse for three months on average.


Earlier data from the study showed that 90 percent of patients experienced a significant improvement in symptoms after just one week of treatment with Ilaris. This rose to 95 percent after two weeks.


(Reporting by Caroline Copley; Editing by Elaine Hardcastle)


Diseases/Conditions News Headlines – Yahoo! News



Read More..

Swiss seek progress on U.S. tax deal: economy minister
















ZURICH (Reuters) – Switzerland hopes to restart talks with the U.S. over a long-simmering tax dispute following the re-election of president Obama, its economy minister was quoted as saying on Sunday.


Switzerland is trying to reach a deal to end investigations by U.S. tax authorities into 11 banks, including Credit Suisse and Julius Baer , suspected of helping clients dodge U.S. taxes with the help of offshore bank accounts.













It needs the tax deal so that it can normalize its banking relations with the United States and wants the investigations dropped in return for the payment of hefty fines by the Swiss banks and the transfer of names of thousands of U.S. clients.


“We are seeking clarification quickly,” Johann Schneider-Ammann told the Zentralschweiz am Sonntag newspaper. “The situation has been blocked recently. That must now change.”


The talks had stalled in the run-up to the U.S. election, and finance minister Eveline Widmer-Schlumpf has suggested the ball is firmly in the U.S. court.


The two countries are at odds over U.S. demands for Switzerland to hand over bank data from before 2009.


In a separate interview with the BaslerZeitung at the weekend, Credit Suisse Chairman Urs Rohner said the unresolved tax deal was a burden.


“We are doing everything that we can and may to resolve the problem. But in the end there is a need for a solution that all involved will have to agree to.”


(Reporting by Caroline Copley; Editing by Elaine Hardcastle)


Economy News Headlines – Yahoo! News



Read More..

Twin explosions strike southern Syrian city
















BEIRUT (AP) — Syria‘s state-run news agency says two large explosions have struck the southern city of Daraa, causing multiple casualties and heavy material damage.


SANA did not immediately give further information or say what the target of Saturday’s explosions was.













The Britain-based Syrian Observatory for Human Rights says the blasts went off near a branch of the country’s Military Intelligence in Daraa.


The Observatory, which relies on a network of activists on the ground, says the explosions were followed by clashes between regime forces and rebels fighting to topple President Bashar Assad.


Middle East News Headlines – Yahoo! News



Read More..

Philip Roth Is Retiring; Amazon Glitch Disables Buy Buttons
















Today in books and publishing: Philip Roth confirms his retirement; Amazon‘s mysteriously vanishing buy buttons; Kobo expands to Italy, Kindle considers China; cities in literature.


RELATED: Trikes, a Mustache, and Andy Warhol













Philip Roth wraps it up. One of America’s most celebrated living novelists has been hinting at retirement for a while now. But he didn’t choose to make a big announcement in a prominent stateside literary organ like The New York Review of Books. He chose instead to let it out in interviews with the foreign press over recent weeks. Last month he told Nelly Kaprièlian of French magazine Les Inrockuptibles that he hasn’t written new material in three years, and doesn’t plan to write any new novels. “To tell you the truth, I’m done,” he said frankly, “Nemesis will be my last book … Enough is enough! I no longer feel this fanaticism to write that I have experienced in my life.” He said the same thing in an interview with Italian magazine La Repubblica earlier this month. His publisher Houghton Mifflin confirmed that Roth is entering retirement. It looks the 74-year-old writer will have plenty of time to go over his life story and thoughts on literature with his new biographer, Blake Bailey. [Salon]


RELATED: How to Game Amazon Prime; Random House Consolidates in the Spanish Market


Where did Amazon‘s buy buttons go? Late last night, customers looking to replenish their Kindles with fresh e-books were probably quite frustrated. No matter how hard anyone clicked, there was no way to purchase e-books from Penguin, Random House, Macmillan, Simon & Schuster, Hachette, and HarperCollins through Amazon. A company spokesperson later confirmed that it was just a technical slip-up, and buy buttons were quickly restored. But given Amazon’s propensity to punish publishers that don’t bend to its will with disabled buy buttons, this brief black-out set off a minor panic in publishing land. Why were only Big Six publishers affected? Did it have anything to do with the ongoing agency pricing legal battles or the Penguin Random House merger? Though it seems to have been nothing more serious than a technical goof, it’s a stark reminder that Amazon has the ability—as well as the leverage—to shut down publishers’ most important connection with consumers at the click of a mouse. [New York Observer]


RELATED: Chart: The Rapid Gains of the E-book


E-reading takes a global turn. E-books may be taking firm holds in the U.S., but they have a long way to go before they became the global format of choice for readers. Italy may be going in an increasingly digital direction soon, with the country’s largest bookseller Mondadori Group partnering with Kobo to stock Touch e-readers in its hundreds of stores. 34,000 e-books will be available for Italian readers. China is another largely untapped market, one that Amazon is eyeing enviously. ZDNet’s Liau Yun Qing reports that Kindles may become available there as early as this month. “If Amazon brings its e-reader to China, it will face competition from Chinese e-commerce player Dangdang which launched its e-reader in July at a retail price of 599 yuan (US$ 79),” she writes. “In comparison, the cheapest Kindle Paperwhite e-reader, which includes “Special Offers”, retails at US$ 119 in the United States.” [ZDNet]


RELATED: New Batman Comic Postponed; Books Banned in China Thrive in Hong Kong


Cities in literature. Mark Binelli’s new book Detroit City Is the Place to Be is all about the Motor City—its ascent during America’s industrial golden age, and its struggle to redefine itself. Given his obsession with the urban, Publishers Weekly decided to tap Binelli for a list of his favorite books that take specific cities as a central theme. It’s more interesting than most lists on this subject might have been. For instance, he shines a light on Joan Didion not for her classic takes on San Francisco or New York, but for her book Miami. And his favorite books to take on New York—Ben Katchor’s The Jew of New York and Joseph Mitchell’s Up in the Old Hotel—are refreshing inclusions. His favorite book about Detroit, Elmore Leonard’s City Primeval, is also a bit surprising. [Publishers Weekly]


Gadgets News Headlines – Yahoo! News



Read More..

Weinstein Co., Clear Channel, Madison Square Garden Hosting Benefit Concert for Sandy Relief
















LOS ANGELES (TheWrap.com) – Clear Channel Media, The Madison Square Garden Company and The Weinstein Company are joining together to produce a benefit concert to raise money for victims of Hurricane Sandy.


The concert, titled “12-12-12,” will feature live music, although the producers did not reveal who would be performing. The roster should be an A-list one though, given that this is the same group of corporate entities that backed “The Concert for New York City,” a star-studded affair with the likes of The Who and Billy Joel on hand to raise money for 9/11.













The concert for Sandy Relief will be held on December 12, 2012, at Madison Square Garden in New York, and the money raised will be dispensed through the Robin Hood Relief Fund.


Hurricane Sandy slammed into the Eastern Seaboard last week, leaving 110 people dead and more than 1 million without power. Damage from the storm is estimated to be between $ 30 billion to $ 50 billion in economic losses.


“12-12-12″ will be produced by James Dolan, executive chairman of The Madison Square Garden Company; John Sykes, president of Clear Channel Entertainment Enterprises; and Harvey Weinstein, co-founder and chairman of The Weinstein Company.


In a joint statement, the producers said: “The Concert for New York City was a night filled with emotion, courage and tremendous hope when we came together as a city following the 9/11 attack. Once again, our city, as well as millions of our neighbors in the tri-state area, are in desperate need of our assistance as they recover from Hurricane Sandy and rebuild their lives. We have no doubt that the event we are planning will be filled with unforgettable music, entertainment and that uniquely American spirit of community, compassion and generosity.”


Music News Headlines – Yahoo! News



Read More..

Gilead posts positive results in mid-stage Hepatitis C study
















(Reuters) – Gilead Sciences Inc on Saturday reported a 100 percent cure rate using a combination of drugs in a small number of patients with the most common and hardest to treat form of hepatitis C.


Rival Abbott Laboratories Inc, meanwhile, said a trio of its oral medicines to treat hepatitis C produced unprecedented cure rates in a larger number of patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients.













Data from both companies’ mid-stage trials were released Saturday at the annual meeting of the American Association for the Study of Liver Disease in Boston.


Gilead’s study, dubbed Electron, examined 25 patients with genotype 1 chronic hepatitis C virus (HCV) infection who were treated for 12 weeks with a combination of three drugs: sofosbuvir, ribavirin and GS-5885.


GS-5885 is from a promising new class of drugs known as NS5A inhibitors, which prevent the hepatitis C virus from replicating.


The infection was undetectable four weeks after completing therapy in all of the patients who had never received this combination of drugs before, Gilead said.


The drugs generally were well tolerated in the study, Gilead said.


In the sofosbuvir combined with GS-5885 and ribavirin patient groups, one patient dropped out because of an adverse side effect that the company said was unrelated to the drugs.


Sofosbuvir and GS-5885 are still being studied for their safety and efficacy.


The biopharmaceutical company will present the data on Tuesday at the annual meeting of the American Association for the Study of Liver Diseases in Boston.


Mark Schoenebaum, a biotech analyst with ISI Group, said in a research note that he expects Gilead shares to rise on Monday based on these “best case” results.


UBS analyst Matthew Roden said “these data strongly support Gilead’s leadership position” in the hepatitis C virus space.


Gilead recently started the first Phase 3 trial evaluating a fixed-dose combination of sofosbuvir and GS-5885 in patients with genotype 1 chronic hepatitis C virus infection who had not received these drugs before.


This study is evaluating the fixed-dose combination with and without ribavirin for 12- and 24-weeks in 800 patients, 20 percent of whom have evidence of cirrhosis, or liver scarring.


(Reporting By Debra Sherman; Editing by Vicki Allen)


Health News Headlines – Yahoo! News



Read More..